Glucocorticosteroid in Treatment of Severe Pneumonia
Joint Authors
Liu, Kaixiong
Jing, Zhang
Ariani, Felinda
Qu, Jieming
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-12-02
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Airway diseases such as pneumonia constitute a major health burden on a global scale; untreated pneumonia may develop to severe pneumonia and consequently lead to to fatal episodes of mortality and morbidity.
The balance between inflammatory mediators is key for the outcome of the pulmonary infection; elimination of invading pathogen was marked by the release of cytokines and other inflammatory mediators from alveolar macrophages and glucocorticoid steroids (GCs) acting on the inflammatory component.
Treatments of severe pneumonia with GCs have been developing for years with inconclusive results.
In many cases GCs have been administered empirically without clinical evidence.
Recent studies assess beneficial impact on treatment of severe pneumonia by suggesting specific dosage, period of administration, and tapered dosage.
American Psychological Association (APA)
Ariani, Felinda& Liu, Kaixiong& Jing, Zhang& Qu, Jieming. 2013. Glucocorticosteroid in Treatment of Severe Pneumonia. Mediators of Inflammation،Vol. 2013, no. 2013, pp.1-8.
https://search.emarefa.net/detail/BIM-504588
Modern Language Association (MLA)
Ariani, Felinda…[et al.]. Glucocorticosteroid in Treatment of Severe Pneumonia. Mediators of Inflammation No. 2013 (2013), pp.1-8.
https://search.emarefa.net/detail/BIM-504588
American Medical Association (AMA)
Ariani, Felinda& Liu, Kaixiong& Jing, Zhang& Qu, Jieming. Glucocorticosteroid in Treatment of Severe Pneumonia. Mediators of Inflammation. 2013. Vol. 2013, no. 2013, pp.1-8.
https://search.emarefa.net/detail/BIM-504588
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-504588